Introduction
In the clinical conditions of decreased renal perfusion, such as nephritic syndrome, liver cirrhosis, heart failure, volume depletion, or aging kidneys, renal prostaglandin (PG) production mediated primarily by cyclooxygenase-1 (COX-1) and possibly by clooxygenase-2 (COX-2) plays a major role in maintaining renal hemodynamics. Inhibition of the synthesis of renal PGs by conventional non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit both COX-1 and COX-2, may result in acute renal complications such as sodium and water retention, hyperkalemia, acute renal failure, and acute papillary necrosis, or chronic renal effects such as nephrotic syndrome, chronic papillary necrosis, and analgesic nephropathy [1] [2] [3] . NSAIDs may also influence blood pressure in treated hypertensive individuals. The COX-2 specific inhibitors were first thought to have much less renal adverse effects by sparing homeostatic COX-1 activity in the kidney. other conditions that tend to compromise renal perfusion. All NSAIDs seem to share these adverse effects.
In view of many NSAIDs users susceptibility to renal adverse effects due to their underlying disease or ' condition, physicians should be cautious in prescribing NSAIDs to susceptible patients.
Edema, Hyponatremia, Renal tubular acidosis, Non-steroidal anti-inflammatory agents, Acute renal failure
Review article
who have underlying diseases), the number of at-risk individuals should be high ( Fig. 1) 
4)
. This review will summarize the possible mechanisms by which fluid and electrolyte abnormalities, acid-base disturbances, and acute renal failure associated with NSAIDs use evolve.
Cyclooxygenase, prostaglandins, and kidney
PGs play active roles in the local regulation of vascular tone and salt and water homeostasis by modulating the glomerular hemodynamics and also by adjusting the function of the distal nephron 5) . In the early 1990s, the existence of two isoforms of cyclooxygenase (COX-1 and COX-2) was confirmed 6) .
COX-1 isoform, which is expressed constitutively in many tissues and catalyzes the PG synthesis, is believed to have physiologic functions including gastric mucosal defense and platelet aggregation. COX-1 is abundantly expressed across species in the collecting ducts, renal vasculature, glomeruli, and papillary interstitial cells 7) . In contrast, basal COX-2 expression in the kidney is less apparent and exhibits some inter-species differences in its localization. COX-2 is constitutive in some tissues and is markedly induced by bacterial endotoxins, cytokines, and growth factors and catalyzes the synthesis of pro-inflammatory PGs.
In addition to their role in preserving renal perfusion, renal PGs promote the secretion of renin, impair sodium reabsorption in the loop of Henle and cortical collecting tubule, and partially antagonize the effect of antidiuretic hormone to increase water reabsorption in the collecting tubules 1, 8) . Locally generated PGs may also mediate part of the natriuretic effect of dopamine and of one of the atrial natriuretic peptides 9) .
These roles of PGs are not very important in normal subjects in whom basal renal PG production is relatively low. However, they may become important when .
COX-2 Expression in the renal medulla
The renal medulla is a major site of prostaglandin synthesis and abundant COX-1 and COX-2 expression. The two cyclooxygenase isoforms exhibit different expression within the medulla, with COX-1 predominating in the medullary collecting duct cells and COX-2 predominating in medullary interstitial cells 14) .
After dehydration, renal medullary COX-2 mRNA and protein expression are significantly induced, primarily in medullary interstitial cells 15) . In contrast, COX-1 expression in the mouse kidney is unaffected by water 
Adverse renal effects of NSAIDs
In the settings of enhanced PGs production, inhibition of PGs synthesis with NSAIDs could, in selected patients, lead to various electrolytes, acid-base disturbances such as hyponatremia, sodium retention, hyperkalemia, or renal tubular acidosis, which are usually reversible with discontinuation of the therapy. This is mediated in part by reduction in the release of renin and aldosterone, which also occurs with selective COX-2 inhibitors. In addition, vasoconstriction due to decreased synthesis of vasodilator PGs can exacerbate underlying hypertension and heart failure.
Sodium excretion
Renal PG has a natriuretic effect via reduced so- .
PGs may also increase medullary blood flow, thus lowering medullary interstitial osmotic driving forces.
Therefore, a PG-dependent, complex, intrarenal short-loop feedback, as well as possible extrarenal mechanisms, may be involved in the renal regulation of water balance (Fig. 4) 21)
. Removal of the inhibitory effect of PGs on antidiuretic hormone (ADH) activity can diminish free water excretion 21) , of which cellular mechanisms is still unclear. [22] [23] [24] .
Edema
Administration of NSAID to human subjects removes the PGs inhibitory effect on sodium and water ' reabsorption, leading to ADH induced water reabsorption and elevation of urine osmolarity that can exceed 200 mOsm/kg H2O, and causes reduction in plasma Na concentration, especially in volume depletion or SIADH (Fig. 5) . In normal subjects, the initial fall in plasma Na will diminish ADH secretion, minimizing water retention. Thus, normal subjects may gain 0.5 to 1 kg,
Prostaglandins
Renal vasodilation shown to result in a 67% increases in the risk of cardiovascular accident and a 15% increase in the risk of coronary artery disease (Fig. 6) 25)
.
Hyperkalemia and renal tubular acidosis
Effects of prostaglandins on renal potassium transport have been described; NSAIDs-associated hyperkalemia appears to be primarily secondary to the effects on aldosterone rather than direct epithelial ef- ; thus loss of this inhibitory action would promote potassium secretion, mitigating rather than exacerbating hyperkalemia 11) . Serum potassium concentration begins to increase upon dosing and attains a new steady state within several days of onset of therapy 18) .
Hyperkalemia is a commonly reported and potentially dangerous complication of treatment with, es- 28) . These observations suggest that selective COX-2 inhibitors should be avoided in patients with chronic renal insufficiency, severe heart disease, volume depletion, and/or hepatic failure.
Compared with celecoxib, the incidence of adverse events related to hypertension and edema were significantly higher with ibuprofen (but not diclofenac), and a decline in renal function was more apparent with diclofenac than with ibuprofen. These data provide a greater understanding of the relative effects of these agents on cardiorenal function and homeostasis 29) .
Conclusion
Both COX-1 and COX-2 are constitutively expressed in the kidney. Prostaglandin enhances the renin secretion in the macula densa. PG induces natriuresis and diuresis by various mechanisms. Inhibition of renal prostaglandin synthesis by NSAIDs 
